Ms. Neha Chugh

CET Group 3 focuses on developments of the international patent system and provides guidance to its users.

Such developments can relate to both substantive and procedural aspects of patent law, and CET3 follows them across jurisdictions.

CET3 identifies issues that deserve study, conducts the studies and provides guidance through various outputs available to the users of the patent system such as Guidelines, Position papers, and Resolutions. CET3 actively contributes to forging and advocating the position of FICPI in discussions on patent law harmonisation in key study and discussion groups such as the Group B+ and at the forums established by WIPO.

CET3 also monitors and studies international agreements and conventions relating to patents, follows the developments of the PCT system and, where necessary, provides comments to WIPO and relevant authorities for defending a well-balanced international patent system.

CET Group 5 is dedicated to following, reporting and providing substantive comments and opinions on emerging issues relating to the patenting and regulatory affairs in the Biotechnology and Pharmaceutical fields. 

In addition, CET 5 is closely following developments related to genetic resources and developing requirements for notice on their country of origin. 

Prominent issues CET 5 addresses regarding patenting in these technological fields include subject matter eligibility, and in particular, the patentability of chemical/biological inventions developed using machines, computer implementation and/or artificial intelligence.  CET 5 supports FICPI in its mission to be an international leader promoting patent protection in the biotechnology and pharmaceutical arts.